1. EPIX shareholders can join a class action lawsuit. 2. Claims include misleading statements on masofaniten's efficacy. 3. Allegations suggest overstated clinical prospects for prostate cancer treatment. 4. The case registration deadline is March 25, 2025. 5. Investors are urged to act swiftly for potential recovery.
The class action highlights significant concerns over the efficacy of EPIX's treatment, similar controversies have historically led to drastic stock declines. For example, companies facing similar allegations often see immediate and sustained drops in stock price as investor confidence wanes.
The article directly addresses investors and legal actions against EPIX, which could lead to substantial stock price effects. The potential for recovery in the lawsuit adds to the urgency.
The imminent registration deadline and current lawsuit will create short-term pressure on EPIX's share price. Such litigation often prompts immediate negative market reactions.
The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).
Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 12, 2023 to October 31, 2024
ALLEGATIONS:
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:
DEADLINE: March 25, 2025
Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=137676&from=4
NEXT STEPS FOR SHAREHOLDERS:
Once you register as a shareholder who purchased shares of EPIX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 25, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM?
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
SOURCE:
Gross Law Firm